DK1545560T3 - Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitus - Google Patents
Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitusInfo
- Publication number
- DK1545560T3 DK1545560T3 DK03770876.5T DK03770876T DK1545560T3 DK 1545560 T3 DK1545560 T3 DK 1545560T3 DK 03770876 T DK03770876 T DK 03770876T DK 1545560 T3 DK1545560 T3 DK 1545560T3
- Authority
- DK
- Denmark
- Prior art keywords
- activity
- treatment
- protein kinase
- diabetes mellitus
- inhibition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10244453A DE10244453A1 (de) | 2002-09-24 | 2002-09-24 | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
| PCT/DE2003/003165 WO2004028516A2 (de) | 2002-09-24 | 2003-09-23 | Zusammensetzungen zur hemmung der proteinkinase c alpha zur behandlung von diabetes mellitus und kardiovaskulärer erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1545560T3 true DK1545560T3 (da) | 2010-11-22 |
Family
ID=31969524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03770876.5T DK1545560T3 (da) | 2002-09-24 | 2003-09-23 | Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitus |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050250719A1 (da) |
| EP (2) | EP1545560B1 (da) |
| JP (1) | JP2006503841A (da) |
| KR (1) | KR20050059180A (da) |
| CN (1) | CN1684694A (da) |
| AT (1) | ATE475422T1 (da) |
| AU (1) | AU2003280288B2 (da) |
| CA (1) | CA2499818A1 (da) |
| DE (3) | DE10244453A1 (da) |
| DK (1) | DK1545560T3 (da) |
| EA (1) | EA007926B1 (da) |
| ES (1) | ES2356286T3 (da) |
| IS (1) | IS7777A (da) |
| MX (1) | MXPA05002930A (da) |
| NO (1) | NO20051242L (da) |
| NZ (1) | NZ538857A (da) |
| PL (1) | PL374829A1 (da) |
| UA (1) | UA88257C2 (da) |
| WO (1) | WO2004028516A2 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| CA2538999A1 (en) * | 2003-09-19 | 2005-03-31 | Children's Hospital Medical Center | Regulation of cardiac contractility and heart failure propensity |
| US8258105B2 (en) * | 2003-10-07 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides optimized for kidney targeting |
| US9144594B2 (en) * | 2005-11-08 | 2015-09-29 | University Of Miami | Cathepsin L mediated diseases and associated methods and products |
| AU2006321727A1 (en) * | 2005-12-09 | 2007-06-14 | Metaproteomics, Llc | Protein kinase modulation by hops and Acacia products |
| WO2007108727A1 (en) * | 2006-03-22 | 2007-09-27 | Leangene Ab | Method for monitoring the effect of compounds on foxc2 expression |
| KR20120091267A (ko) | 2007-01-31 | 2012-08-17 | 바이오석세스 바이오텍 컴퍼니 | 포르볼 에스테르 조성물과 그의 사용 방법 |
| US9533938B2 (en) | 2007-01-31 | 2017-01-03 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| US10369222B2 (en) | 2012-01-18 | 2019-08-06 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| US11696908B2 (en) | 2007-01-31 | 2023-07-11 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters |
| US9636317B2 (en) | 2007-01-31 | 2017-05-02 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters |
| US9974764B2 (en) | 2007-01-31 | 2018-05-22 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters in the treatment of neoplasms |
| US11564901B2 (en) | 2007-01-31 | 2023-01-31 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters |
| EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
| WO2011041584A2 (en) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
| DK2637672T3 (da) | 2010-11-12 | 2018-10-22 | Gentium S R L | Defibrotid til anvendelse i profylakse og/eller behandling af graft versus host sygdom (gvhd) |
| US9550722B2 (en) | 2012-01-18 | 2017-01-24 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbal esters for the treatment of stroke |
| US10099996B2 (en) | 2012-01-18 | 2018-10-16 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters in the treatment of neoplasms |
| KR102102677B1 (ko) * | 2012-01-18 | 2020-04-22 | 바이오석세스 바이오텍 컴퍼니 리미티드 | 포르볼 에스테르의 조성물 |
| US20150079111A1 (en) * | 2012-06-05 | 2015-03-19 | Jonas Axelsson | Mechanism, diagnostic, and treatments for complications of renal failure |
| WO2013190582A1 (en) | 2012-06-22 | 2013-12-27 | Gentium S.P.A. | Euglobulin-based method for determining the biological activity of defibrotide |
| TWI750481B (zh) * | 2013-01-18 | 2021-12-21 | 美商華鴻新藥股份有限公司 | 用於中風治療之巴豆酯組成物及使用方法 |
| TWI687217B (zh) * | 2014-01-10 | 2020-03-11 | 華鴻新藥股份有限公司 | 用於中風治療之巴豆酯組成物及使用方法 |
| EP3099312B1 (en) | 2014-01-29 | 2018-12-05 | Université de Strasbourg | New target for diabetes treatment and prevention |
| CN106458993A (zh) * | 2014-04-14 | 2017-02-22 | 阿尔维纳斯股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| WO2017004151A1 (en) | 2015-06-29 | 2017-01-05 | Regents Of The University Of Minnesota | Anti-apobec3 antibodies and methods of making and using |
| EP3421485A1 (en) | 2017-06-30 | 2019-01-02 | Université de Strasbourg | Peptides for treatment and prevention of hyperglycaemia |
| CN111386240A (zh) * | 2017-09-29 | 2020-07-07 | 安全工程有限责任公司 | 具有直流电源的提升机系统 |
| RU2765117C2 (ru) * | 2019-09-24 | 2022-01-25 | Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" | Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета |
| WO2022092884A1 (ko) * | 2020-10-29 | 2022-05-05 | 가톨릭관동대학교산학협력단 | 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3914764A1 (de) * | 1989-05-05 | 1990-11-08 | Goedecke Ag | Maleinimid-derivate und deren verwendung als arzneimittel |
| DE3924538A1 (de) * | 1989-07-25 | 1991-01-31 | Goedecke Ag | Indolocarbazol und dessen verwendung |
| HUT64837A (en) * | 1990-10-01 | 1994-03-28 | Brigham & Womens Hospital | Preparatives of beta-carotine and those of vitamine e having ulceration inhibiting effect |
| HUT64295A (en) * | 1990-11-02 | 1993-12-28 | Sphinx Pharma Corp | Method for producing bis-(hydroxy-alkyl-amino)-anthraquinone derivatives as well as pharmaceutical preparatives containing them |
| AU1783092A (en) * | 1991-04-08 | 1992-11-02 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | Inhibitors of protein kinase c function |
| EP0817627B1 (en) | 1993-12-23 | 2005-03-09 | Eli Lilly And Company | Protein kinase c inhibitors |
| US5491242A (en) | 1994-06-22 | 1996-02-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| US5481003A (en) | 1994-06-22 | 1996-01-02 | Eli Lilly And Company | Protein kinase C inhibitors |
| US5710145A (en) * | 1995-11-20 | 1998-01-20 | Eli Lilly And Company | Protein kinase C inhibitor |
| WO1997041127A1 (en) * | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Halo-substituted protein kinase c inhibitors |
| US6063814A (en) * | 1997-04-14 | 2000-05-16 | Chang; Richard L. | Phorbol esters as anti-neoplastic and white blood cell elevating agents |
| DE19740384A1 (de) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
| CA2538999A1 (en) * | 2003-09-19 | 2005-03-31 | Children's Hospital Medical Center | Regulation of cardiac contractility and heart failure propensity |
-
2002
- 2002-09-24 DE DE10244453A patent/DE10244453A1/de not_active Withdrawn
-
2003
- 2003-09-23 MX MXPA05002930A patent/MXPA05002930A/es active IP Right Grant
- 2003-09-23 NZ NZ538857A patent/NZ538857A/en unknown
- 2003-09-23 UA UAA200503856A patent/UA88257C2/ru unknown
- 2003-09-23 DE DE50312935T patent/DE50312935D1/de not_active Expired - Lifetime
- 2003-09-23 DK DK03770876.5T patent/DK1545560T3/da active
- 2003-09-23 PL PL03374829A patent/PL374829A1/xx unknown
- 2003-09-23 WO PCT/DE2003/003165 patent/WO2004028516A2/de active Application Filing
- 2003-09-23 AT AT03770876T patent/ATE475422T1/de active
- 2003-09-23 CN CNA038228017A patent/CN1684694A/zh active Pending
- 2003-09-23 JP JP2004538744A patent/JP2006503841A/ja active Pending
- 2003-09-23 ES ES03770876T patent/ES2356286T3/es not_active Expired - Lifetime
- 2003-09-23 KR KR1020057004958A patent/KR20050059180A/ko not_active Application Discontinuation
- 2003-09-23 EP EP03770876A patent/EP1545560B1/de not_active Expired - Lifetime
- 2003-09-23 US US10/528,806 patent/US20050250719A1/en not_active Abandoned
- 2003-09-23 EA EA200500529A patent/EA007926B1/ru not_active IP Right Cessation
- 2003-09-23 CA CA002499818A patent/CA2499818A1/en not_active Abandoned
- 2003-09-23 DE DE10393825T patent/DE10393825D2/de not_active Expired - Fee Related
- 2003-09-23 EP EP10170970A patent/EP2338498A1/de not_active Withdrawn
- 2003-09-23 AU AU2003280288A patent/AU2003280288B2/en not_active Ceased
-
2005
- 2005-03-10 NO NO20051242A patent/NO20051242L/no not_active Application Discontinuation
- 2005-03-30 IS IS7777A patent/IS7777A/is unknown
-
2008
- 2008-12-01 US US12/325,930 patent/US20090191194A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1684694A (zh) | 2005-10-19 |
| DE10393825D2 (de) | 2005-08-11 |
| NO20051242L (no) | 2005-06-01 |
| NZ538857A (en) | 2010-10-29 |
| PL374829A1 (en) | 2005-10-31 |
| DE10244453A1 (de) | 2004-04-01 |
| CA2499818A1 (en) | 2004-04-08 |
| EP2338498A1 (de) | 2011-06-29 |
| ES2356286T3 (es) | 2011-04-06 |
| UA88257C2 (ru) | 2009-10-12 |
| EA200500529A1 (ru) | 2005-08-25 |
| EP1545560B1 (de) | 2010-07-28 |
| EP1545560A2 (de) | 2005-06-29 |
| EA007926B1 (ru) | 2007-02-27 |
| DE50312935D1 (de) | 2010-09-09 |
| ATE475422T1 (de) | 2010-08-15 |
| AU2003280288B2 (en) | 2008-08-28 |
| US20090191194A1 (en) | 2009-07-30 |
| WO2004028516A2 (de) | 2004-04-08 |
| US20050250719A1 (en) | 2005-11-10 |
| AU2003280288A1 (en) | 2004-04-19 |
| IS7777A (is) | 2005-03-30 |
| MXPA05002930A (es) | 2005-09-30 |
| KR20050059180A (ko) | 2005-06-17 |
| WO2004028516A3 (de) | 2004-11-11 |
| JP2006503841A (ja) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1545560T3 (da) | Sammensætninger til inhibering af proteinkinase C-alfa til behandling af diabetes mellitus | |
| ES2531660T3 (es) | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio | |
| NO20044534L (no) | Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer | |
| RS51449B (sr) | Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija | |
| NZ551801A (en) | Quinazolinedione derivatives as PARP inhibitors | |
| WO2003044015A3 (en) | Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors | |
| NO20062292L (no) | Fremgangsmate for behandling av transplantasjonsavstoting | |
| MY147642A (en) | Novel anthranilamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors | |
| DK1176956T3 (da) | Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer | |
| DE602005008412D1 (de) | Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen | |
| ZA200408772B (en) | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia. | |
| WO2002066450A3 (en) | Anthrone derivatives and their use as ink inhibitors | |
| DK1349843T3 (da) | Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer | |
| WO2004024093A3 (en) | Device and method for treating restenosis | |
| ATE485049T1 (de) | Physiologisch aktive zusammensetzung gegen diabetes | |
| NO20083068L (no) | Optisk aktive karbamater, fremgangsmate for deres fremstilling og anvendelse derav som farmasoytiske mellomprodukter | |
| NO20072803L (no) | Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer | |
| BR0017157A (pt) | Derivados de 6-hidroxi-indazol para o tratamento de glaucoma | |
| RS50804B (sr) | Derivati 2-(1h-indolilsulfanil)-arila za primenu u lečenju afektivnih poremećaja, bola, poremećaja pažnje i hiperaktivnosti (adhd) i stres urinarne inkontinencije | |
| EP1602645A4 (en) | NITROGENIC HETEROCYCLIC DERIVATIVE WITH 2,6-DISUBSTITUTED STYRYL REST | |
| DK1587584T3 (da) | Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdomme | |
| ECSP045222A (es) | INHIBIDORES DE LA ADHESION CELULAR MEDIADA POR INTEGRINA aLb2 | |
| WO2002006280A3 (en) | INHIBITORS OF FACTOR Xa | |
| WO2000048447A3 (en) | Composition for treatment of external secretion disorders except hypolacrimation | |
| NO20062527L (no) | Nitrooksyderivater av antihypertensive legemidler |